Try a new search

Format these results:

Searched for:

in-biosketch:true

person:mdk230

Total Results:

129


Rouvière's Sulcus: An External Landmark for Safe Dissection when the Critical View Cannot Be Achieved

Cawich, Shamir O; Pearce, Neil W; Kluger, Michael; Dapri, Giovanni; Alseidi, Adnan; Johnson, Shaneeta; Ramkissoon, Solange C K; Gardner, Michael T; Cawich, Isabelle K; Shetty, Ramnanand
BackgroundIntraoperative identification of Rouvière's sulcus is a proposed strategy to prevent bile duct injuries. Since it marks the plane at which the extra-hepatic ducts lie, limiting surgical dissection ventral to Rouvière's sulcus should protect the ducts from injury. This is an important adjunct when the critical view of safety cannot be achieved during difficult cholecystectomies.MethodsThis was an observational study of all consecutive elective laparoscopic cholecystectomies between January 1, 2017 and May 30, 2024. Intraoperatively, Rouvière's sulcus was identified by surgeons, with correlation by an independent observer. The relationship between the sulcus and the right hepatic pedicle was confirmed by laparoscopic ultrasound. Comparisons were made using SPSS.ResultsOver 7 years, 356 laparoscopic cholecystectomies were performed, and Rouvieré's sulcus could be identified in 296 (83.2%) patients. When a well-defined sulcus was present, it correlated reliably to the right portal triad in all cases. However, the reliability of this relationship significantly reduced in the absence of a well-defined sulcus (100% vs 5%; P < 0.0001).ConclusionsWhen present, Rouvieré's sulcus is a valuable asset to surgeons, who can use it as a landmark for safe dissection planes during cholecystectomies. When a well-defined sulcus is absent, surgeons should employ alternative means of bile duct protection, such as indocyanine green or operative cholangiography.
PMID: 42215020
ISSN: 1555-9823
CID: 6075699

Association of irreversible electroporation treatment with overall survival in Stage III pancreatic ductal adenocarcinoma: DIRECT registry results

Martin Ii, Robert C G; White, Rebekah Ruth; Bilimoria, Malcolm M; Narayanan, Govindarajan; Kluger, Michael D; Iannitti, David A; Polanco, Patricio M; Hammill, Chet W; Cleary, Sean P; Heithaus, Robert Evans; Welling, Theodore; Chan, Carlos H F
BACKGROUND:Irreversible electroporation (IRE) is used in selected patients with Stage III pancreatic ductal adenocarcinoma (PDAC), but its association with survival relative to standard-of-care (SOC) therapy remains uncertain. METHODS:This multicenter observational study included 137 patients from the DIRECT registry: 99 treated within an IRE-based strategy and 38 receiving SOC without IRE. Overall survival (OS) from diagnosis was evaluated using propensity-score overlap weighting as the principal adjusted analysis. Conventional inverse probability of treatment weighting (IPTW), propensity-score matching, 3- and 6-month landmark analyses, and a time-dependent Cox model treating IRE as a time-varying exposure were sensitivity analyses. Restricted mean survival time (RMST) at 24 months was estimated. RESULTS:Median time from diagnosis to enrollment was 8 months (IQR, 6-10) with IRE and 4 months (IQR, 3-6) with SOC (P < .0001). Unadjusted median OS was 28 months (95% CI, 23-33) and 15 months (95% CI, 12-21), respectively. Overlap weighting was associated with lower mortality with IRE (HR, 0.28; 95% bootstrap CI, 0.12-0.48). Twenty-four-month RMST was 21.22 vs 16.24 months, an absolute difference of 4.99 months (95% bootstrap CI, 1.15-8.12). The time-dependent analysis attenuated but retained the association (HR, 0.59; 95% bootstrap CI, 0.37-0.94). Other sensitivity analyses were directionally consistent. CONCLUSIONS:An IRE-based treatment strategy was associated with longer OS than SOC without IRE. Attenuation in the time-dependent analysis indicates that treatment timing and selection contributed to the observed difference. Given the nonrandomized design and potential residual confounding, these findings demonstrate association rather than an independent causal effect of IRE.
PMCID:13722508
PMID: 42872478
ISSN: 1549-490x
CID: 6074707

ASO Visual Abstract: Post-Pancreatectomy Liver Injury after Mayo Clinic Class Ia Celiac Axis Resection: Illustration of This Newly Described Entity with Delayed Hepatic Artery Revascularization

Garnier, Jonathan; Amabile, Philippe; Palen, Anaïs; Gonzalez, Frederic; Faucher, Marion; Mokart, Djamel; Poizat, Flora; Mari, Roxane; Tresson, Philippe; Ewald, Jacques; Izaaryene, Jean; Marchetti, Alessio; Marchegiani, Giovanni; Kluger, Michael D; Wolfgang, Christopher L; Turrini, Olivier
PMID: 42758447
ISSN: 1534-4681
CID: 6072955

High grade PanIN is associated with malignancy risk in IPMN patients

Hunter, Madeleine D; Habib, Joseph R; Hidalgo Salinas, Camila; Levine, Jonah M; Mlouk, Kate; Hewitt, D Brock; Cohen, Noah A; Morgan, Katherine A; Kluger, Michael D; Cao, Wenqing; Javed, Ammar A; Wolfgang, Christopher L; Sacks, Greg D
PMID: 42705945
ISSN: 1424-3911
CID: 6072205

Does ductal subtype predict outcomes after resection of IPMN-derived pancreatic cancer? An international multi-center retrospective study

Mlouk, Kate; Hidalgo Salinas, Camila; Levine, Jonah; Habib, Joseph R; Hunter, Madeleine; Imam, Rami; Hewitt, D Brock; Kluger, Michael D; Morgan, Katherine; Daamen, Lois A; Wolfgang, Christopher L; Molenaar, I Quintus; Besselink, Marc G; Javed, Ammar A; Sacks, Greg D
BACKGROUND:Although main duct (MD) and branch duct (BD) IPMNs differ in preoperative risk of malignant transformation, it remains unclear whether ductal subtype influences outcomes once invasive carcinoma develops and is resected. We compared recurrence and survival outcomes between these subtypes. METHODS:We identified patients with resected IPMN-derived pancreatic ductal adenocarcinoma (PDAC) from three institutions. Overall survival (OS) and recurrence-free survival (RFS) were estimated using Kaplan-Meier methods and compared with log-rank tests. Multivariable Cox regression models adjusted for age, T-stage, N-stage, histologic subtype, and adjuvant chemotherapy. RESULTS:Among 136 patients, 106 (78%) had MD-derived and 30 (22%) had BD-derived IPMN-associated PDAC. Median OS was 36.6 months and did not differ by subtype on log-rank (p = 0.472) or multivariable analysis (HR 0.45, 95% CI 0.15-1.31; p = 0.143). Median RFS was 41.8 months without significant difference by subtype on log-rank (p = 0.362) or adjusted analysis (HR 0.56, 95% CI 0.21-1.46; p = 0.234). CONCLUSIONS:In patients with resected IPMN-derived PDAC, ductal subtype was not significantly associated with OS. While clinically meaningful differences in RFS cannot be excluded, these findings suggest that once invasive cancer arises and is resected, ductal subtype alone may not provide additional prognostic information.
PMID: 42692902
ISSN: 1477-2574
CID: 6072017

Post-pancreatectomy Liver Injury After Mayo Clinic Class Ia Celiac Axis Resection: Illustration of This Newly Described Entity with Delayed Hepatic Artery Revascularization

Garnier, Jonathan; Amabile, Philippe; Palen, Anaïs; Gonzalez, Frederic; Faucher, Marion; Mokart, Djamel; Poizat, Flora; Mari, Roxane; Tresson, Philippe; Ewald, Jacques; Izaaryene, Jean; Marchetti, Alessio; Marchegiani, Giovanni; Kluger, Michael D; Wolfgang, Christopher L; Turrini, Olivier
Resection of the celiac artery (CA) during surgery for locally advanced pancreatic cancer (LAPC) carries a significant risk of hepatic and gastric ischemia.1,2 In addition, in the current context, where patients undergo intensive chemotherapy before surgery, a new complication has emerged: post-pancreatectomy liver injury (PPLI).3 PATIENT AND METHODS: A 59-year-old patient with biopsy-confirmed locally advanced pancreatic cancer arising from the pancreatic body (Video and Fig. 1) underwent extended neoadjuvant FOLFIRINOX (folinic acid [leucovorin], fluorouracil, irinotecan, and oxaliplatin). The patient was restaged using the A-B-C criteria,4 adding the target approach for anatomical feasibility,5 metabolic imaging, and survival prediction.6 Fig. 1 Preoperative planning and first operation: extended pancreatosplenectomy, including resection of the left adrenal gland and the celiac artery (CA) (Mayo Clinic class Ia), divestment of the superior mesenteric artery, and portal vein (PV)-superior mesenteric vein reconstruction using a left renal vein graft interposition (A and B). Abdominal phase computed tomography scan, axial view, showing the encasement of the CA but with a free proper hepatic artery (PHA) as a "suitable target" if needed. (C) Drawing of the tumoral involvement with CA encasement and left/anterior side of the superior mesenteric artery (SMA) abutment. PHA, gastroduodenal artery (GDA), and the biliary tract were free of tumor, allowing a Mayo Clinic class Ia CA resection. 15 mm was the distance measured from the tumor to the GDA, and 28 mm was the distance of SMA abutment on the left side. (D) Operative view highlighting the common hepatic artery (CHA) stump, the remnant head of the pancreas (HoP), the venous reconstruction with left renal vein interposition graft, SMA divestment, and the CA stump. IVC, inferior vena cava; LGA, left gastric artery; LGV, left gastric vein; LRV, left renal vein; SA, splenic artery; SMV, superior mesenteric vein PERIOPERATIVE MANAGEMENT: The patient underwent extended pancreatosplenectomy, including resection of the left adrenal gland and the CA (Mayo Clinic class Ia), divestment of the superior mesenteric artery, and portal-superior mesenteric vein reconstruction using a left renal vein graft interposition. Arterial reconstruction was initially deemed unnecessary, as proper hepatic artery flow was maintained-albeit dampened-via the gastroduodenal artery, confirmed by visual inspection and Doppler ultrasound. Postoperatively, the course was notable for a rapid rise in alanine aminotransferase levels without overt clinical or radiological deterioration (Fig. 2). Emergency re-exploration was undertaken with the objective of hepatic arterial revascularization (Fig. 3). We hypothesized that, in the setting of underlying metabolic dysfunction-associated steatotic liver disease, arterial inflow was insufficient to meet the demands of an already vulnerable parenchyma, with increased intrahepatic resistance further compounding ischemic liver injury consistent with clinically relevant (CR)-PPLI. Liver biopsy confirmed acute steatohepatitis and extensive ischemic necrosis. Fig. 2 Postoperative liver enzyme kinetics during the first postoperative week. Alanine aminotransferase (ALT) levels demonstrated a sharp and rapid increase from the day of surgery to postoperative day (POD) 2, leading to re-operation for a supercharged hepatic artery (HA) revascularization. Following revascularization, ALT levels decreased promptly, with complete normalization of liver biochemical parameters by POD 7. AST, aspartate aminotransferase; CAR, celiac artery resection; INR, international normalized ratio POD, postoperative day Fig. 3 Second surgical procedure: final reconstruction and liver biopsy. (A) Drawing of the final reconstruction with a zoom (B) on the arterial bypass between the right renal artery and the common hepatic artery. (C) Liver biopsy showing acute steatohepatitis, with 75% macro- and micro-vesicular steatosis and extensive ischemic necrosis. (D) Zoom on the area of ischemic necrosis, showing infiltration of the liver by neutrophils, lymphocytes, and plasma cells. CA, celiac artery; CHA, common hepatic artery; GDA, gastroduodenal artery; GSV, great saphenous vein; HoP, head of pancreas; IVC, inferior vena cava; LGA, left gastric artery; LGV, left gastric vein; LRV, left renal vein; PHA, proper hepatic artery; PV, portal vein; RRA, right renal artery; RRV, right renal vein; SMA, superior mesenteric artery; SMV, superior mesenteric vein CONCLUSION: Early postoperative recognition and grading of CR-PPLI is critical to prevent liver failure, as static imaging may fail to reflect dynamic hepatic perfusion. A disproportionate rise in alanine aminotransferase within 48 h is a key warning sign. Prospective multicenter studies are needed to better define the incidence, risk factors, and optimal management of CR-PPLI.
PMID: 42668340
ISSN: 1534-4681
CID: 6071864

Rethinking imaging-based IPMN subtype classification: is mixed-type a necessary radiologic category?

Liu, Timothy; Shen, Yiqiu; Chen, Yuxuan; Chen, Anna; Kim, Jesi; Hung, Yu Chih; Pasadyn, Felicia; Miller, Frank H; Kluger, Michael D; Huang, Chenchan
PURPOSE/OBJECTIVE:To evaluate radiology-pathology concordance and interobserver agreement of intraductal papillary mucinous neoplasm (IPMN) subtype classification, and to determine whether categorical subtype classification adds value for malignancy risk stratification beyond main pancreatic duct (MPD) features. METHODS:In this single-center retrospective study, 144 consecutive patients who underwent surgical resection of an IPMN between 2005 and 2025 and had preoperative CT or MRI within 6 months of surgery were included. Images were independently reviewed by two blinded radiologists, with discrepancies adjudicated by a third. Adjudicated radiologic subtype classification was used for radiology-pathology concordance, logistic regression, and receiver operating characteristic (ROC) analyses; interobserver agreement was assessed using the independent reader interpretations. Logistic regression and ROC analyses identified predictors of malignancy. RESULTS:Overall radiology-pathology concordance under the radiologic classification was 60.4% (87/144). Among pathologic mixed-type IPMNs, 60.3% (38/63) were classified as branch-duct IPMNs on imaging. Interobserver agreement was moderate for radiologic subtype (κ = 0.509) but excellent for MPD diameter (ICC = 0.909). On multivariable analysis, MPD diameter independently predicted malignancy (aOR, 1.31; 95% CI, 1.12-1.53; p = .001), whereas radiologic subtype was not. MPD diameter outperformed radiologic subtype for discrimination of malignancy (AUC, 0.737 vs. 0.624; p = .001). Adding radiologic subtype to MPD diameter provided no incremental discriminative value for malignancy (AUC, 0.739 vs. 0.737; p = .61). CONCLUSION/CONCLUSIONS:Radiologic IPMN subtype classification demonstrated only modest concordance with pathology and moderate interobserver agreement. MPD diameter demonstrated higher interobserver agreement and superior discrimination for IPMN malignancy risk stratification. These findings suggest that the mixed-type IPMN subtype may not be necessary as a distinct category for malignancy risk stratification, and that greater emphasis on objective MPD measurement may provide a more reproducible and clinically informative approach.
PMID: 42560493
ISSN: 2366-0058
CID: 6070847

EUS-guided drainage of symptomatic postoperative fluid collections: a retrospective cohort study evaluating timing of intervention and clinical outcomes

Raza, Muhammad H; Tiao, Jonathan R; Wang, Catherine K; Luk, Lyndon; Doyle, John B; Sugahara, Kazuki N; Schrope, Beth A; Kluger, Michael D; Chabot, John A; Manji, Gulam; Gonda, Tamas A; Welinsky, Sara; Poneros, John M; Sethi, Amrita; Visrodia, Kavel H
BACKGROUND:Symptomatic postoperative fluid collections (POFCs) can result in significant morbidity and mortality after abdominal surgery requiring timely intervention. EUS-guided drainage is traditionally delayed up to four weeks to allow wall maturation and reduce perforation or peritonitis risk. However, some POFCs may be suitable for earlier intervention. This study compared the efficacy and safety of acute (≤ 15 days), early (16-30 days), and delayed (> 30 days) EUS-guided drainage. METHODS:A retrospective cohort of patients undergoing EUS-guided drainage for symptomatic POFCs between 2013 and 2023 at a single tertiary center was evaluated. Technical success was defined as accessing and draining a POFC by transmural stent placement on initial endoscopy. Clinical success was defined as radiographically or endosonographically confirmed symptomatic POFC improvement without further percutaneous or surgical intervention. RESULTS:Among 85 patients with POFCs, most (61%) had undergone distal pancreatectomy with splenectomy. 59% required drainage ≤ 30 days after surgery, with 28% managed acutely. Most (83%) received lumen-apposing metal stents. Overall technical and clinical success rates were 94% and 79%, respectively, after a median 2 endoscopies (IQR 2-3). Success did not differ by timing (technical: 92% vs. 96% vs. 94%; clinical: 83% vs. 85% vs. 71%; P = 0.86 and P = 0.37). Adverse event rates were similar across groups (P = 0.85). Transgastric access was associated with clinical success (P < 0.001) and fewer adverse events (P = 0.03). Transduodenal access predicted technical (P = .05) and clinical failure (P = 0.02). CONCLUSIONS:In this large single-center experience of symptomatic POFCS, acute and early EUS-guided drainage with lumen-apposing metal stents in carefully selected patients was found to be technically safe and clinically effective, potentially avoiding more morbid interventions such as ERCP, percutaneous drainage, or surgery. Further randomized, prospective studies are needed to define predictors of technical and clinical success as well as adverse events.
PMID: 42230364
ISSN: 1432-2218
CID: 6043842

Postpancreatectomy liver injury: A relevant entity in the modern era of pancreatic cancer surgery with hepatic vessel resection. A monocentric retrospective cohort study

Marchetti, Alessio; Salinas, Camila H; Garnier, Jonathan; Andel, Paul C M; Habib, Joseph R; Perri, Giampaolo; Ratner, Molly; Rompen, Ingmar F; De Pastena, Matteo; Salvia, Roberto; Marchegiani, Giovanni; Javed, Ammar A; Hewitt, Brock; Sacks, Greg D; Levine, Jamie P; Garg, Karan; Morgan, Katherine A; Wolfgang, Christopher L; Kluger, Michael D
BACKGROUND:Advances in pancreatic cancer surgery involve hepatotoxic chemotherapies and hepatic vasculature resections, increasing the risk of clinically relevant postpancreatectomy liver injury. The study aimed to analyze the incidence and impact of clinically relevant postpancreatectomy liver injury after pancreatectomy with hepatic vessel resection. METHODS:In this single-institutional study, patients undergoing pancreatectomy with resection of hepatic vessels (portal vein/superior mesenteric vein, celiac axis, and hepatic arteries) were analyzed. Arterial lactate, total bilirubin, alanine aminotransferase, aspartate aminotransferase, international normalized ratio, and Doppler ultrasound-derived resistive index were assessed postoperatively. Postoperative outcomes were assessed through 90 days. Clinically relevant postpancreatectomy liver injury was defined as American Association for the Study of Liver Diseases-defined liver failure and/or need for invasive treatment of liver complications. RESULTS:Among 116 patients (67% portal vein/superior mesenteric vein resection alone, 7% celiac axis/hepatic arteries alone, 26% portal vein/superior mesenteric vein + celiac axis/hepatic artery resection), 15 (13%) developed clinically relevant postpancreatectomy liver injury. Mortality was significantly higher in the clinically relevant postpancreatectomy liver injury group (47% vs 3%; P < .001). The proper hepatic artery resistive index was lower in the clinically relevant postpancreatectomy liver injury group (0.52 vs 0.65; P = .034), whereas the following 48-hour-peak blood tests were significantly higher in this group: Lac, bilirubin, aspartate aminotransferase, and alanine aminotransferase (all P < .01). Combined portal vein/superior mesenteric vein + celiac axis/hepatic arteries and elevated alanine aminotransferase 48-hour peak above 1680 U/L remained significantly associated with the occurrence of clinically relevant postpancreatectomy liver injury in multivariable analyses. Forty percent of clinically relevant postpancreatectomy liver injury occurred in the absence of vascular complications. CONCLUSION/CONCLUSIONS:Clinically relevant postpancreatectomy liver injury is associated with significant mortality. Low resistive index and markedly elevated biochemical markers within the first 48 hours correlate with clinically relevant postpancreatectomy liver injury and may be used to trigger earlier intervention. Given the associated morbidity and mortality, defining, preventing, and mitigating clinically significant postpancreatectomy liver injury is of the utmost importance.
PMID: 42173064
ISSN: 1532-7361
CID: 6038802

Development and Validation of a Parsimonious Risk Stratification Model for Pancreatic Cancer

Mavromatis, Lucas A; Zlatanic, Viktor; Agarunov, Emil; Sanoba, Shenin A; Kluger, Michael D; Horwitz, Leora I; Razavian, Narges; Maitra, Anirban; Gonda, Tamas A; Grams, Morgan E
IMPORTANCE/UNASSIGNED:Pancreatic ductal adenocarcinoma (PDAC) is a leading cause of cancer deaths in the US. Although early detection improves survival, the rarity of the disease has rendered population screening a difficult approach. OBJECTIVE/UNASSIGNED:To develop and validate a parsimonious, interpretable, and generalizable model predicting incident PDAC-termed PRIME (PDAC Risk Model for Earlier Detection)-using routinely available electronic health record (EHR) data. DESIGN, SETTING, AND PARTICIPANTS/UNASSIGNED:This cohort study used the Optum Labs Data Warehouse, a longitudinal, deidentified US EHR and claims database. Adults 40 years or older with an outpatient clinical encounter between 2016 and 2018 were included. Participants from 23 health systems (n = 4 859 833) comprised the training cohort; 31 additional systems (n = 5 619 091) served as validation. International validation was conducted in the UK Biobank (n = 498 754). Data analysis occurred July 2025 to January 2026. EXPOSURES/UNASSIGNED:Demographics, diagnosis codes, and routinely measured laboratory values were evaluated. Elastic-net regularization with 10-fold cross-validation selected the predictor set. MAIN OUTCOMES AND MEASURES/UNASSIGNED:Incident PDAC was identified by International Classification of Diseases, Ninth and Tenth Revisions (ICD-9/10) codes. Model performance was assessed using time-dependent area under the curve (AUC) and calibration metrics. RESULTS/UNASSIGNED:Overall, the study included more than 11 million adults (2.1% Asian individuals, 8.4% Black individuals, 4.3% Hispanic/Latino individuals, 82.7% White individuals, and 2.4% other race/ethnicity by EHR reporting). In the training cohort (mean [SD] age, 60.4 [11] years), 14 405 individuals were diagnosed with PDAC (incidence 55 per 100 000 person-years) over a mean (SD) of 5.4 (2.5) years; in the validation cohort, 11 693 individuals were diagnosed with PDAC (54 per 100 000 person-years) over a mean (SD) of 3.9 (2.5) years. PRIME retained 19 predictors including history of pancreatitis, gastrointestinal disorders, prior cancers, type 2 diabetes, elevated aspartate aminotransferase levels, smoking, non-type-O blood, and male sex. Discrimination was strong at the 36-month time horizon (AUC = 0.75 in both the training and validation cohorts) with good calibration. In the validation cohort, patients in the top 1% of predicted risk had substantially higher PDAC risk (HR, 7.63; 95% CI, 6.85-8.49) compared with average-risk patients. In the UK Biobank, PRIME achieved a 36-month AUC of 0.71 with good calibration. CONCLUSIONS AND RELEVANCE/UNASSIGNED:In this validation cohort study, PRIME was a transparent EHR-based model that effectively stratified PDAC risk across diverse US health systems and generalized internationally. Prospective studies should evaluate for EHR-guided PDAC case-finding and integration with blood-based early-detection assays.
PMCID:13022769
PMID: 41885821
ISSN: 2374-2445
CID: 6018542